Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + Liposomal Doxorubicin in RRMM
NCT02186834Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Sep 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by Moffitt Cancer Center. Started Sep 2014; status: completed.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02186834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02186834.